article thumbnail

Taking a new approach to tackle neurodegenerative diseases

Drug Discovery World

William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . Overcoming sector challenges . Furthermore, the global need is about seven times greater than the US.

article thumbnail

Informatics helps virtual biotech bring compound to clinical trial

Drug Discovery World

Libra Therapeutics is a San Diego-based biotech focused on developing novel disease-modifying therapeutics, which restore the cellular balance that is disrupted in neurodegenerative diseases. This article is sponsored by Collaborative Drug Discovery. Users can also export data into Excel, so outgoing files can be password protected.